Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy in the past decade and amplify T-cell-mediated immune responses by disrupting immunoinhibitory signals. The augmented T-cell immune response has led to a range of immune-related adverse effects (irAEs). Immune-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Junjuan, Li, Xingyu, Wang, Xuan, Guan, Yaping, Liu, Hairong, Liang, Jing, Li, Yan, Wang, Baocheng, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115988/
https://www.ncbi.nlm.nih.gov/pubmed/37089888
http://dx.doi.org/10.3389/fcvm.2023.1093383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115988/
https://www.ncbi.nlm.nih.gov/pubmed/37089888
http://dx.doi.org/10.3389/fcvm.2023.1093383

Ejemplares similares